Last updated: March 26, 2026
What is the drug identified by NDC 69584-0853?
NDC 69584-0853 corresponds to Venclexta (venetoclax) tablets. It is indicated for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), often in combination with other therapies. Manufactured by AbbVie, venetoclax has gained regulatory approval from the FDA since its initial approval in 2016, with subsequent indications and expanded labeling.
What is the current market size and growth potential?
Market Size
The global hematologic oncology drugs market, which includes venetoclax, was valued at approximately $6.5 billion in 2022 and is expected to reach $11.8 billion by 2027. The growth rate (compound annual growth rate, CAGR) is projected at 12.6%.
Key drivers:
- Rising prevalence of CLL and SLL worldwide.
- Increased adoption of targeted therapies over chemotherapies.
- Expanded indications for venetoclax, including acute myeloid leukemia (AML) and other hematologic malignancies.
Competitor Landscape
Main competitors include:
- Ibrutinib (Imbruvica, Pharmacyclics/Janssen)
- Obinutuzumab (Gazyva, Roche)
- Idelalisib (Zydelig, Gilead Sciences)
- New entrants and biosimilars are developing, but venetoclax maintains a significant share due to its efficacy.
Market Penetration
- The drug primarily targets US, European, and certain Asian markets.
- In the US, penetration in eligible patient populations exceeds 70%.
- The drugs are prescribed primarily in second-line and combination regimens.
What are the key factors influencing the price?
Pricing Overview
- Average Wholesale Price (AWP): Approx. $7,350 per 30 tablets (100 mg).
- Direct acquisition cost: Estimated at $3,000 to $4,000 per month after discounts and rebates.
- Patient out-of-pocket (OOP): Usually ranges from 10-25% of retail prices, depending on insurance plans and assistance programs.
Pricing Trends
- Prices are stable due to patent protection until at least 2030.
- ART (average retail price) for a standard 30-day supply ranges from $5,000 to $8,000.
- Discount programs and authorization processes reduce actual costs for insurers and patients.
Impact of Biosimilars and Competition
- Currently, limited biosimilar competition exists in hematological oral therapies.
- Price reductions are unlikely before patent expiration; however, contractual negotiations may influence net prices.
What is the outlook for price projections?
Short-term (1-3 years)
- Prices will likely hold steady, supported by patent exclusivity and high clinical demand.
- No significant patent litigations or generic entry expected until at least 2029.
Medium-term (4-7 years)
- Potential for gradual price erosion starting 2029, with patent expiry.
- Entry of biosimilar or generic versions could reduce prices by 30-50%, similar to trends seen with other oncology drugs.
- Expansion of label indications may sustain demand and niche pricing.
Long-term (8+ years)
- Post-patent expiry, prices could stabilize at significantly lower levels.
- Market share shifts with the introduction of newer therapies or combination treatments.
What are regulatory and policy impacts?
- U.S. regulatory pathways favoring accelerated approvals and label expansions will sustain demand.
- Cost-containment policies (e.g., rebates, value-based pricing, and formulary restrictions) may influence net prices.
- International markets face pricing negotiations aligned with local healthcare budgets and policies.
Summary comparison table
| Aspect |
Current Status |
Future Outlook |
| Market size |
~$6.5 billion (2022), projected to reach $11.8 billion by 2027 |
Growth driven by usage expansion, CAGR 12.6% |
| Pricing (AWP) |
~$7,350 per 30 tablets |
Stable short-term, possible decline post-patent |
| Patent expiry |
Likely around 2029 |
Biosimilars and generics entry, risk of 30-50% cut |
| Competitors |
Ibrutinib, obinutuzumab, idelalisib |
Continued competition, possibly moderate price drops |
| Regulatory environment |
Favorable for label expansions |
Increased pressures for value-based models |
Key Takeaways
- NDC 69584-0853 (Venclexta) remains a high-value product with steady demand and limited immediate competition.
- Prices are estimated at roughly $7,350 per month, with potential for marginal decreases upon patent expiration.
- The market growth is driven by expanding indications and persistent unmet needs in hematological malignancies.
- Biosimilar and generic entries expected around 2029 could lead to substantial price reductions.
- Market share and pricing will be affected by healthcare policy developments and competitive innovations.
FAQs
1. When does the patent protection for venetoclax expire?
Expected around 2029, based on patent filings and extensions.
2. Are biosimilars available for venetoclax?
No approved biosimilars exist as of the latest data; oral small-molecule drugs like venetoclax are less susceptible to biosimilar development.
3. How does venetoclax compare in price to competitors?
Its AWP (~$7,350 for 30 tablets) exceeds many oral targeted therapies but is comparable within oncology prices; demand and exclusivity influence this.
4. What are the main drivers of market growth?
Expanding indications, increased diagnosis rates, and inclusion in combination regimens.
5. How might pricing be affected by healthcare policy?
Reimbursement models prioritizing value-based care can pressure prices downward, especially post-patent expiry.
References
[1] MarketsandMarkets. (2023). Hematologic oncology drugs market report.
[2] U.S. Food and Drug Administration. (2016). FDA approval notification for venetoclax.
[3] IQVIA. (2022). National prescription data.
[4] EvaluatePharma. (2023). Oncology drugs market forecasts.
[5] AbbVie. (2023). Venclexta prescribing information.
